Good new positive intention3 Jul 2024 09:48
GSK licensing deal with CureVac for flu and Covid drugs
Nasdaq-listed CureVac will receive an upfront payment of EUR400 million, and up to an additional EUR1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range.
GSK said the agreement represents the latest step in its ongoing investment in vaccine platform technologies.